Mangoceuticals Inc. Common Stock (MGRX)

FairStock Score: 42/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I start with the business, not the stock chart. Mangoceuticals runs a telemedicine platform selling men's wellness products under Mango, Grow, Mojo, and Slim, with only 3 employees. That is an asset-light model, but I see no durable moat: it is a tiny marketer of products that larger telehealth and pharmaceutical firms can copy or outspend. The figures confirm fragility. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $68,757 and net income was -$1.3M. In fiscal Q2 2025, the quarter ended 2025-06-30, revenue was $168,109 and net income was -$5.4M, so sales fell sharply even though the loss narrowed. In FY2025, the year ended 2025-12-31, revenue was $456,021 and net income was -$20.6M. In FY2024 revenue was $615,873 and net income was -$8.7M; in FY2023 revenue was $731,493 and net income was -$9.2M. Sales are shrinking while losses are enormous relative to revenue. Free cash flow was -$3.9M trailing twelve months, a -48.5% FCF yield on an $8.0M market cap. At the close on 2026-10-13, the price was $0.37; FairStock calculations show P/B 0.54 and P/E -0.37, with ROE -95.10% and Altman Z-score -1.90. Low debt-to-equity of 0.02 is a small comfort, but negative equity returns, cash burn, and a Lynch category of none because of four straight loss years tell me this is speculation, not a Graham-style bargain. I need evidence of sustainable revenue and self-funding before calling it a business.

In plain English: Mangoceuticals sells men's health products through a telemedicine platform, including treatments for erectile dysfunction, hair loss, hormone balance, and weight loss. The business is very small and has been losing money, with sales shrinking and more cash going out than coming in. The recent share price may look low compared with the company's accounting value, but the weak losses and cash burn mean it does not look cheap based on business results.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer